NASDAQ:ARCT Arcturus Therapeutics (ARCT) Stock Price, News & Analysis $13.74 +0.87 (+6.76%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$13.52 -0.22 (-1.56%) As of 10/9/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arcturus Therapeutics Stock (NASDAQ:ARCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arcturus Therapeutics alerts:Sign Up Key Stats Today's Range$12.87▼$14.3250-Day Range$6.00▼$16.9352-Week Range$5.50▼$24.17Volume675,624 shsAverage Volume821,257 shsMarket Capitalization$390.49 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingModerate Buy Company Overview Arcturus Therapeutics Holdings Inc. is a biotechnology company focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. Headquartered in San Diego, California, the company uses its proprietary LUNAR lipid-mediated delivery platform and STX self-amplifying mRNA technology to design and deliver RNA-based therapeutics and vaccines. The company’s research and development activities address rare diseases, infectious diseases, respiratory conditions and other areas of significant unmet medical need. Its pipeline has included mRNA-based treatments for metabolic and genetic disorders, including ornithine transcarbamylase deficiency, as well as programs designed to address cystic fibrosis and other conditions. Arcturus has also developed RNA-based vaccine candidates, including a self-amplifying mRNA COVID-19 vaccine developed in collaboration with CSL. Arcturus was founded in 2013 and has entered into collaborations and licensing arrangements with pharmaceutical companies and other organizations to advance its technologies. The company is led by Joseph E. Payne, who serves as president and chief executive officer. Its activities are primarily focused on research, clinical development and strategic partnerships supporting the development of RNA medicines for patients worldwide.AI Generated. May Contain Errors. Read More Arcturus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks57th Percentile Overall ScoreARCT MarketRank™: Arcturus Therapeutics scored higher than 57% of companies evaluated by MarketBeat, and ranked 299th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingArcturus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 1 strong buy rating, 7 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArcturus Therapeutics has a consensus price target of $22.00, representing about 60.1% upside from its current price of $13.74.Amount of Analyst CoverageArcturus Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Arcturus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arcturus Therapeutics are expected to decrease in the coming year, from ($3.48) to ($3.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcturus Therapeutics is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcturus Therapeutics is -4.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcturus Therapeutics has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Arcturus Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.02% of the float of Arcturus Therapeutics has been sold short.Short Interest Ratio / Days to CoverArcturus Therapeutics has a short interest ratio ("days to cover") of 5.93.Change versus previous monthShort interest in Arcturus Therapeutics has recently decreased by 1.64%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcturus Therapeutics does not currently pay a dividend.Dividend GrowthArcturus Therapeutics does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentArcturus Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arcturus Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 7 people have searched for ARCT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Arcturus Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcturus Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.80% of the stock of Arcturus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.54% of the stock of Arcturus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arcturus Therapeutics' insider trading history. Receive ARCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcturus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARCT Stock News HeadlinesReviewing Arcturus Therapeutics (NASDAQ:ARCT) and Precigen (NASDAQ:PGEN)October 8 at 4:59 AM | americanbankingnews.comWells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)October 6, 2026 | theglobeandmail.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. | Chaikin Analytics (Ad)Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Rating of "Moderate Buy" from AnalystsOctober 6, 2026 | americanbankingnews.comArcturus Therapeutics (NASDAQ:ARCT) Rating Lowered to "Sell" at Wall Street ZenOctober 4, 2026 | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Arcturus Therapeutics (ARCT)October 3, 2026 | theglobeandmail.comAnalysts Are Bullish on Top Healthcare Stocks: Arcturus Therapeutics (ARCT), ACADIA Pharmaceuticals (ACAD)September 25, 2026 | theglobeandmail.comArcturus Therapeutics Shares Rise After OTC Deficiency Data, Citigroup UpgradeSeptember 24, 2026 | marketscreener.comMSee More Headlines ARCT Stock Analysis - Frequently Asked Questions How have ARCT shares performed this year? Arcturus Therapeutics' stock was trading at $6.13 at the beginning of the year. Since then, ARCT shares have increased by 124.1% and is now trading at $13.74. How were Arcturus Therapeutics' earnings last quarter? Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings data on Friday, August, 7th. The biotechnology company reported ($0.84) EPS for the quarter, beating analysts' consensus estimates of ($1.00) by $0.16. The biotechnology company had revenue of $2.96 million for the quarter, compared to analyst estimates of $3.11 million. Arcturus Therapeutics had a negative net margin of 317.62% and a negative trailing twelve-month return on equity of 46.54%. Read the conference call transcript. Who are Arcturus Therapeutics' major shareholders? Top institutional investors of Arcturus Therapeutics include Green Alpha Advisors LLC (0.10%) and Versant Capital Management Inc (0.01%). View institutional ownership trends. How do I buy shares of Arcturus Therapeutics? Shares of ARCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcturus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcturus Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and CrowdStrike (CRWD). Company Calendar Last Earnings8/07/2026Today10/09/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ARCT's financial health is in the Green zone, according to TradeSmith. ARCT has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARCT CIK1768224 Webwww.arcturusrx.com Phone(858) 900-2660FaxN/AEmployees111Year Founded2013Price Target and Rating Average Price Target for Arcturus Therapeutics$22.00 High Price Target$41.00 Low Price Target$9.00 Potential Upside/Downside+60.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$65.78 million Net Margins-317.62% Pretax Margin-317.64% Return on Equity-46.54% Return on Assets-36.46% Debt Debt-to-Equity RatioN/A Current Ratio5.88 Quick Ratio5.88 Sales & Book Value Annual Sales$82.03 million Price / Sales4.76 Cash FlowN/A Price / Cash FlowN/A Book Value$7.53 per share Price / Book1.82Miscellaneous Outstanding Shares28,420,000Free Float23,364,000Market Cap$390.49 million OptionableOptionable Beta2.48 Social Links Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (NASDAQ:ARCT) was last updated on 10/10/2026 by MarketBeat.com Staff. From Our PartnersA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredThis free guide explains options the way they should be taughtMost options educators jump straight into Greeks, spreads, and implied volatility - losing beginners before th...Base Camp Trading | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA simple options setup that cuts through the noiseIan Cooper says most options traders overcomplicate the process, juggling countless indicators, strategies, an...TradeWins | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredLook at Elon’s face after meeting with ChinaElon Musk recently met with Chinese President Xi Jinping, and a former Wall Street Journal Personal Finance Ex...International Living | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ARCT Stock Alerts